Assessment of Self-Administration of Romiplostim in Patients with Immune Thrombocytopenic Purpura after Receipt of Home Administration Training Materials: a Cross-Sectional Study

What Was Tested

The paper reports a study of Romiplostim, published as an observational study.

The primary objective was to estimate the proportion of patients/caregivers who administered romiplostim correctly after HAT pack training.

Why It Was Studied

Romiplostim is a subcutaneously administered thrombopoietin-receptor agonist approved in the European Union for self-administration (or administration by a caregiver) in selected adult patients with chronic primary immune thrombocytopenia refractory to other treatments.

To mitigate the risk of medication errors due to self-administration, the manufacturer has implemented additional risk minimisation measures (RMM) in the form of a Home Administration Training (HAT) pack to support the training of both healthcare professionals (HCPs) (guide and checklist for patient selection and training) and patients (a preparation mat, quick guide booklet, step-by-step guide, self-administration diary and DVD/video).

Who Took Part

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The design is described as multicenter.

More than one site took part, so the participants came from several places.

What Was Measured

Romiplostim is a subcutaneously administered thrombopoietin-receptor agonist approved in the European Union for self-administration (or administration by a caregiver) in selected adult patients with chronic primary immune thrombocytopenia refractory to other treatments.

To mitigate the risk of medication errors due to self-administration, the manufacturer has implemented additional risk minimisation measures (RMM) in the form of a Home Administration Training (HAT) pack to support the training of both healthcare professionals (HCPs) (guide and checklist for patient selection and training) and patients (a preparation mat, quick guide booklet, step-by-step guide, self-administration diary and DVD/video).

Topics PubMed links to this paper include Cross-Sectional Studies, Home Care Services, Pamphlets, Patient Education as Topic, Purpura, Thrombocytopenic, Idiopathic, Receptors, Fc and Recombinant Fusion Proteins.

What This Means in Plain Language

The paper is a multicenter study of Romiplostim.

Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Drug safety), a journal based in New Zealand.

More context: the Romiplostim compound page, all human trials.